This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


RIBOMIC, Inc.
【Field/Business】
Pharmaceutical/Drug Discovery
Pharmaceutical/Drug Discovery
Pharmaceutical/Drug Discovery
last update:2019/8/28
Profile

Delegates :
Yoshikazu Nakamura


Incorporated :
August  1 , 2003

Paid in Capital :
3261 Million yen  

Employees :
20 人

Address :
Shirokanedai Usui Build. Minato-ku. Shirokanedai 3-16-13 TOKYO
〒108-0071

TEL/FAX :
81-3-3440-3303 / 81-3-3440-3729

URL:
https://www.ribomic.com/eng/index.php

Attachment :

Mission/Background :
RIBOMIC Inc. is a biopharmaceutical venture company based in Tokyo.
The RiboART System can be applied to develop variety of aptamer pharmaceuticals. We aim to provide new drugs for a wide range of Unmet Medical Needs, including ophthalmic disorders, pain, fibrosis, and bone diseases.

subsidiary: RIBOMIC USA Inc.
2120 University Ave,Berkeley,CA 94704 USA
CEO Yusuf Ali

Technology & Business
The Ribomic Aptamer Refined Therapeutics (RiboART) system is the core of RIBOMIC drug discovery technology. Overall, it consists of technology, expertise, and experience in aptamer drug discovery and constitutes a variety of platforms that underlie new drug discoveries. By applying the RiboART system, it is possible to discover various new drugs essentially applicable to any target proteins, and not limited to one disease.
Aptamer therapeutics has the following advantages over antibody drugs:Higher binding affinity to target proteins, Fewer limitations as to targets, Easier chemical modification, Production by chemical synthesis, and Lower antigenicity.
Products & Service
Products & Service Name
Stage
Outline
Milestone
RBM-007
Phase1/2
anti FGF2 aptamer for age-related degeneration(AMD)
to start phase2 clinical trial, to license
RBM-007
Preclinical
anti FGF2 aptamer for Achondroplasia (ACH)
to start clinical study, to license
RBM-003
Preclinical
anti Cymase aptamer for Heart Failure
to start clicical study, to license
RBM-010
Preclinical
anti ADAMTS5 aptamer for osteoarthritis(OA)
to start clinical study, to license
IgG aptamer (RBM-101)
Service/Marketing
Affinity purification of human IgG and Fc-fusion proteins
to license
Highlights
2019.6 RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration
2019.1 Entered into a cooperative research agreement with Vitamin C60 BioResearch Corporation
2018.12 THE PRITZKER NEUROPSYCHIATRIC DISORDERS RESEARCH CONSORTIUM SIGNS A MATERIAL TRANSFER AGREEMENT WITH RIBOMIC INC.
2018.9 RIBOMIC’s Joint Project Selected for the CREST Program
Hot news

Alliance strategy
to license in-house products including RBM-007 (anti FGF2 aptamer) .
to collaborate with pharmaceutical company, diagnostics company, and cosmetics company using our aptamer discovery technology.


 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.